449 related articles for article (PubMed ID: 35657320)
1. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Tie J; Cohen JD; Lahouel K; Lo SN; Wang Y; Kosmider S; Wong R; Shapiro J; Lee M; Harris S; Khattak A; Burge M; Harris M; Lynam J; Nott L; Day F; Hayes T; McLachlan SA; Lee B; Ptak J; Silliman N; Dobbyn L; Popoli M; Hruban R; Lennon AM; Papadopoulos N; Kinzler KW; Vogelstein B; Tomasetti C; Gibbs P;
N Engl J Med; 2022 Jun; 386(24):2261-2272. PubMed ID: 35657320
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
3. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
5. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
[TBL] [Abstract][Full Text] [Related]
6. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
Folprecht G; Reinacher-Schick A; Weitz J; Lugnier C; Kraeft AL; Wisser S; Aust DE; Weiss L; von Bubnoff N; Kramer M; Thiede C; Tannapfel A
Clin Colorectal Cancer; 2022 Jun; 21(2):170-174. PubMed ID: 34772609
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
8. "Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".
Taïeb J; Benhaim L; Laurent Puig P; Le Malicot K; Emile JF; Geillon F; Tougeron D; Manfredi S; Chauvenet M; Taly V; Lepage C; André T
Dig Liver Dis; 2020 Jul; 52(7):730-733. PubMed ID: 32482534
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
Tie J; Wang Y; Tomasetti C; Li L; Springer S; Kinde I; Silliman N; Tacey M; Wong HL; Christie M; Kosmider S; Skinner I; Wong R; Steel M; Tran B; Desai J; Jones I; Haydon A; Hayes T; Price TJ; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Sci Transl Med; 2016 Jul; 8(346):346ra92. PubMed ID: 27384348
[TBL] [Abstract][Full Text] [Related]
10. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Meyerhardt JA; Shi Q; Fuchs CS; Meyer J; Niedzwiecki D; Zemla T; Kumthekar P; Guthrie KA; Couture F; Kuebler P; Bendell JC; Kumar P; Lewis D; Tan B; Bertagnolli M; Grothey A; Hochster HS; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF
JAMA; 2021 Apr; 325(13):1277-1286. PubMed ID: 33821899
[TBL] [Abstract][Full Text] [Related]
11. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
Sahin IH; Lin Y; Yothers G; Lucas PC; Deming D; George TJ; Kopetz S; Lieu CH; Dasari A
Oncology (Williston Park); 2022 Oct; 36(10):604-608. PubMed ID: 36260786
[TBL] [Abstract][Full Text] [Related]
12. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
13. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin (3 months
Kim ST; Kim SY; Lee J; Yun SH; Kim HC; Lee WY; Kim TW; Hong YS; Lim SB; Baek JY; Oh JH; Ahn JB; Shin SJ; Han SW; Kim SG; Kang SY; Sym SJ; Zang DY; Kim YH; Choi IS; Kang JH; Kim MJ; Park YS
J Clin Oncol; 2022 Nov; 40(33):3868-3877. PubMed ID: 35772045
[TBL] [Abstract][Full Text] [Related]
15. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Vernieri C; Galli F; Ferrari L; Marchetti P; Lonardi S; Maiello E; Iaffaioli RV; Zampino MG; Zaniboni A; De Placido S; Banzi M; Damiani A; Ferrari D; Rosati G; Labianca RF; Bidoli P; Frassineti GL; Nicolini M; Pavesi L; Tronconi MC; Buonadonna A; Ferrario S; Re GL; Adamo V; Tamburini E; Clerico M; Giordani P; Leonardi F; Barni S; Ciarlo A; Cavanna L; Gori S; Cinieri S; Faedi M; Aglietta M; Antista M; Dotti KF; Galli F; Di Bartolomeo M;
Oncologist; 2019 Mar; 24(3):385-393. PubMed ID: 30606884
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
[TBL] [Abstract][Full Text] [Related]
17. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
Slater S; Bryant A; Chen HC; Begum R; Rana I; Aresu M; Peckitt C; Zhitkov O; Lazaro-Alcausi R; Borja V; Powell R; Lowery D; Hubank M; Rich T; Anandappa G; Chau I; Starling N; Cunningham D
BMC Cancer; 2023 Mar; 23(1):257. PubMed ID: 36941575
[TBL] [Abstract][Full Text] [Related]
18. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
Alarid-Escudero F; Schrag D; Kuntz KM
Value Health; 2022 Mar; 25(3):409-418. PubMed ID: 35227453
[TBL] [Abstract][Full Text] [Related]
19. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
20. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
Shah MA; Renfro LA; Allegra CJ; André T; de Gramont A; Schmoll HJ; Haller DG; Alberts SR; Yothers G; Sargent DJ
J Clin Oncol; 2016 Mar; 34(8):843-53. PubMed ID: 26811529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
